Información del artículo
Los nódulos tiroideos son muy frecuentes y afectan aproximadamente al 10% de la población general. La citología tras aspiración con aguja fina es uno de los puntos de partida en la evaluación del nódulo tiroideo y su precisión es excelente, pero las muestras de citología sospechosas o indeterminadas son un dilema diagnóstico y de conducta a seguir. Se ha intentado buscar un marcador o marcadores moleculares útiles para la ayuda al diagnóstico citológico y se han analizado más de 70 moléculas con este propósito. En esta revisión se orienta sobre todo al estudio de algunos, como peroxidasa tiroidea, tiroglobulina, telomerasa, galectina 3, RET/PTC y proteína p53; de ellos, unos pocos, como la peroxidasa tiroidea, la tiroglobulina y la galectina 3, se pueden estudiar en el laboratorio habitual y son prometedores, aunque no cumplen todos los criterios requeridos para su uso en la práctica clínica. La guía estadounidense y el consenso europeo para la conducta a seguir ante el nódulo tiroideo y el cáncer diferenciado de tiroides no recomiendan su utilización, ya que las evidencias que presentan son insuficientes.
Palabras clave:
Citología tras punción-aspiración con aguja fina
Peroxidasa tiroidea
Tiroglobulina
Telomerasa
Galectina 3
RET/PTC
Proteína p53
Thyroid nodules are common, affecting approximately 10% of the general population. Fine-needle aspiration biopsy has become the mainstay of thyroid nodule evaluation. The overall accuracy of this procedure is excellent but suspicious or indeterminate cytological samples can pose a diagnostic and management dilemma. In the attemptto find a molecular marker useful as an aid for cytological diagnosis, at least 70 molecular markers have been analyzed in thyroid nodules. This review focuses on some potential markers, such as thyroid peroxidase, thyroglobulin, telomerase, galectin-3, RET/PTC and p53; a few of these potential markers, such as thyroid peroxidases, thyroglobulin and galectin-3, can be studied in routine pathology laboratories and are promising, but do not yet fulfill the criteria for use in clinical practice. The American guidelines and the European consensus for the management of thyroid nodules and differentiated thyroid cancer do not recommend their use because the evidence provided is insufficient.
Key words:
Fine-needle aspiration biopsy
Thyroid peroxidase
Thyroglobulin
Telomerase
Galectin-3
RET/PTC
p53
El Texto completo está disponible en PDF
Bibliografía
[1.]
Gómez JM. Cáncer de tiroides. Tiroides. En: Diéguez González C, Yturriaga Matarranz R, editores. Madrid: McGraw-Hill/Interamericana; 2007. p. 253-65.
[2.]
D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.L. Mandel, et al.
Mangement guidelines for patients with thyroid nodules and differentiated thyroid cancer.
Thyroid, 16 (2006), pp. 1-33
[3.]
F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, W. Wiersinga, The European Thyroid Cancer Taskforce.
European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium.
Eur J Endocrinol, 154 (2006), pp. 787-903
[4.]
B.R. Haugen, W.W. Woodmansee, M.T. McDermott.
Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumors.
Clin Endocrinol (Oxf), 56 (2002), pp. 281-290
[5.]
M. Sahin, A. Gursoy, N.B. Tutuncu, D.N. Guvener.
Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules.
Clin Endocrinol (Oxf), 65 (2006), pp. 514-518
[6.]
K.P. Letsas, M. Andrikoula, A. Tsatsoulis.
Fine needle aspiration biopsy-RT-PCR molecular analysis of thyroid nodules: a useful preoperative diagnostic tool.
Minerva Endocrinol, 31 (2006), pp. 179-182
[7.]
T. Murakawa, H. Tsuda, T. Tanimoto, T. Tanabe, S. Kitahara, O. Matsubara.
Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therepeutic approach.
Pathol Intern, 55 (2005), pp. 757-765
[8.]
E. Kebebew, M. Peng, E. Reiff, Q.-Y. Duh, O.H. Clark, A. McMillan.
ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.
Ann Surg, 242 (2005), pp. 353-363
[9.]
M. Fryknäs, U. Wickenberg-Bolin, H. Göransson, M.G. Gustafsson, T. Foukakis, J.-J. Lee, et al.
Molecular markers for discrimination of benign and malignant follicular thyroid tumors.
Tumor Biol, 27 (2006), pp. 211-220
[10.]
S.L. Asa.
The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.
Endocr Pathol, 16 (2005), pp. 295-309
[11.]
D.L. Segev, D.P. Clark, M.A. Zeiger, C. Umbricht.
Beyond the suspicious thyroid fine needle aspirate. A review.
Acta Cytol, 47 (2003), pp. 709-722
[12.]
J.F. Hewnry, A. Denizot, A. Porcelli, M. Villafane, P. Zoro, S. Garcia, et al.
Thyroperoxidase immunodetection for the diagnosis of malignancy on fine-needle aspiration of thyroid nodules.
World J Surg, 18 (1994), pp. 529-534
[13.]
C. De Micco, V. Vassko, J.F. Henry.
The value of thyroid peroxidase immunochemistry for preoperative fine-needle aspiration diagnosis of the follicular variant of papillary thyroid cancer.
Surgery, 12 (1999), pp. 1200-1204
[14.]
S. Savin, D. Cvejic, T. Isic, I. Paunovic, S. Tatic, M. Havelka.
The efficacy of the thyroid peroxidase marker for distinguising follicular thyroid carcinoma from follicular adenoma.
Exp Oncol, 28 (2006), pp. 70-74
[15.]
D. Fuhrer, M. Eszlinger, S. Karger, K. Krause, C. Engelhardt, D. Hasenclever, et al.
Evaluation of insulin-like growth factor II, cycloosygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumors.
Eur J Endocrinol, 152 (2005), pp. 785-790
[16.]
E.A. Kogan, E.B. Rozhkova, V.P. Seredin, M.A. Paltsev.
Prognostic value of the expression of thyroglobulin and oncomarkers (p53, EGFR, ret-oncogene) in different types of papillary carcinoma of the thyroid: clinicomorphological and immunohistochemical studies.
Arkh Patol, 68 (2006), pp. 8-11
[17.]
F. Boi, G. Baghino, F. Atzeni, M.L. Lai, G. Faa, S. Mariotti.
The diagnostic value for differentiated thryoid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies.
J Clin Endocrinol Metab, 91 (2006), pp. 1364-1369
[18.]
N. Cunha, F. Rodrigues, F. Curadeo, O. Ilhéu, C. Cruz, P. Naidenov, et al.
Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer.
Eur J Endocrinol, 157 (2007), pp. 101-107
[19.]
K. Wagner, R. Arciaga, A. Siperstein, M. Milas, I. Warshawsky, S. Sethu, et al.
Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: diagnosis synergy for detecting thyroid cancer.
J Clin Endocrinol Metab, 90 (2005), pp. 1921-1924
[20.]
S.L. Wang, W.T. Chen, M.T. Wu, H.M. Chan, S.F. Yang, C.Y. Chai.
Expression of human telomerase reverse transcriptase in thyroid follicular neoplasms: an immunohistochemical study.
Endocr Pathol, 16 (2005), pp. 211-218
[21.]
E. Lerma, J. Mora, The Thyroid Study Group.
Telomerase activity in “suspicous” thyroid cancer.
Cancer Cytophol, 105 (2005), pp. 492-497
[22.]
P.L. Fernández, M.J. Merino, M. Gómez, E. Campo, T. Medina, V. Castronovo, et al.
Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
J Pathol, 181 (1997), pp. 80-86
[23.]
J.F. Collet, I. Hurbain, C. Prengel, O. Utzmann, F. Scetbon, J.F. Beranaudin, et al.
Galectin-3 immunodetection in follicular thryoid neoplasms: a prospective study on fine-needle aspiration samples.
Br J Cancer, 93 (2005), pp. 1175-1181
[24.]
Y. Ito, H. Yoshida, C. Tomoda, A. Miya, K. Kobayashi, F. Matsuzuka, et al.
Galectin-3 expression in follicular tumors: and immunohistochemical study af its use as a marker of follicular carcinoma.
Pathology, 37 (2005), pp. 296-298
[25.]
P. De Matos, A.P. Ferreira, F. De Oliveira Facuri, L.V.M. Saaumpçao, K. Metze, L.S. Ward.
Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaning in the diagnosis of thyroid malignancy.
Histopathology, 47 (2005), pp. 391-401
[26.]
D. Cvejic, S. Savin, I. Petrovic, S. Selemetjev, I. Paunovic, S. Tatic, et al.
Galectin-3, proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.
Exp Oncol, 27 (2005), pp. 210-214
[27.]
M. Aron, K. Kapila, K. Verma.
Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Indian J Pathol Microbiol, 49 (2006), pp. 376-380
[28.]
E.D. Rossi, M. Rafaelli, A. Mule, A. Miraglia, C.P. Lombardi, F.M. Vecchio, et al.
Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Histopathology, 48 (2006), pp. 795-800
[29.]
T. Scognamiglio, E. Hyjek, J. Kao, Y.T. Chen.
Diagnostic usefulness of HBME1, galectin-3, CK19 and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.
Am J Clin Pathol, 126 (2006), pp. 700-708
[30.]
M.J. Kim, H.J. Kim, S.J. Hong, Y.K. Shong, G. Gong.
Diagnostic utilility of galectin-3 in aspirates of thyroid follicular lesions.
Acta Cytol, 50 (2006), pp. 28-34
[31.]
P. Mehrotra, A. Okpokam, R. Bouhaidar, S.J. Johnson, J.A. Wilson, B.R. Davis, et al.
Galectin-3 does not eliably distinguish benign from malignant thyroid neoplasms.
Histopathology, 45 (2004), pp. 493-500
[32.]
C.C. Cheung, B. Carydis, S. Ezzat, Y.C. Bedard, S.L. Asa.
Analysis of ret/PTC gene rearangements refines the fine needle aspiration diagnosis of thyroid cancer.
J Clin Endocrinol Metab, 86 (2001), pp. 2187-2190
[33.]
B. McIver, S.K. Grebe, N.L. Eberhardt.
The PAX-8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma.
Curr Drug Targets Immune Endocr Metabol Disord, 4 (2004), pp. 221-234
[34.]
T. Dwight, S.R. Thopp, T.T. Foukakis, W.O. Lui, G. Wallin, A. Höög, et al.
Involvement of the PAX8/peroxisome proliferator-activated receptor g rearrangement in follicular thyroid tumors.
J Clin Endocrinol Metab, 88 (2003), pp. 4440-4445
[35.]
L. Lacroix, C. Mian, T. Barrier, M. Talbot, B. Caillou, M. Schlumberger, et al.
PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malinant thyroid tissues.
Eur J Endocrinol, 151 (2004), pp. 367-374
[36.]
W.-O. Lui, T. Foukakis, J. Lidén, S.R. Thoppe, T. Dwight, A. Höög, et al.
Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARg fusion oncogene.
Oncogene, 24 (2005), pp. 1467-1476
[37.]
M.N. Nikiforova, R.A. Lynch, P.W. Biddinger, E.K. Alexander, G.W. Dorn, G. Tallini, et al.
RAS point mutation and PAX8PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
J Clin Endocrinol Metab, 88 (2003), pp. 2318-2326
[38.]
J. Di Cristofaro, M. Silvy, A. Lanteaume, M. Marcy, P. Carayon, C. De Micco.
Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes.
Endocr Rel Cancer, 13 (2006), pp. 485-495
[39.]
Y. Ito, H. Yoshida, C. Tomoda, T. Uruno, Y. Takamura, A. Miya, et al.
Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma.
Pathol Res Pract, 201 (2005), pp. 545-549
[40.]
C.A. Pickett, S.N. Agoff, T.J. Widman, M.P. Bronner.
Altered expression of cyclines and cell cycle inhibitors i papillary thryod cancer: prognostic implications.
Thyroid, 15 (2005), pp. 461-473
[41.]
Y. Ito, K. Arai, Y. Ryushi, H. Yoshida, T. Uruno, C. Tomoda, et al.
S100A9 expression is sinificantly linked to dedifferentiation of thyroid carcinma.
Pathol Res Pract, 201 (2005), pp. 545-549
[42.]
C. Ensinger, R. Kresmer, R. Prommegger, G. Spizzo, K.W. Schmid.
EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases.
Immunother, 29 (2006), pp. 569-573
[43.]
V.S. Chandan, W.C. Faquin, D.C. Wilbur, K.K. Khurana.
The role of immunolocalization of CD57 and GLUT-1 in cell bloks in fine-needle aspiration diagnosis of papillary thyroid carcinoma.
Cancer Cytopathol, 108 (2006), pp. 331-336
[44.]
P. Mehrotra, M.A. González, S.J. Johnson, N. Coleman, J.A. Wilson, B.R. Davis, et al.
Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy.
Laryngoscope, 116 (2006), pp. 1434-1438
[45.]
E. Kebebew, M. Peng, E. Reiff, Q.Y. Duh, O.H. Clark, A. McMillan.
ECM1 and TMPRSS4 are diagnostic markers of malignant thyrod neoplasms and improve the accuracy of fine needle aspiration biopsy.
Ann Surg, 242 (2005), pp. 353-363
[46.]
J.M. Cerutti, F.R.M. Latini, C. Nakabashi, R. Delcelo, V.P. Andrade, M.J. Amadei, et al.
Diagnosis of suspicious thyroid nodules using four protein biomarkers.
Clin Cancer Res, 12 (2006), pp. 3311-3318
[47.]
D.J. Finley, C.C. Lubitz, C. Wei, B. Zhu, T.J. Fahey III.
Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling.
Thyroid, 15 (2005), pp. 562-568
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición